Loading...
•
Mar 31
ImmunityBio Q1 2025 Earnings Report
ImmunityBio reported doubled net revenue and 150% unit growth in Q1 2025, with continued strong sales momentum following the issuance of a J-code for ANKTIVA.
Key Takeaways
ImmunityBio achieved significant growth in the first quarter of 2025, with net product revenue increasing by 129% to $16.5 million, driven by strong sales of ANKTIVA. The company also saw a 150% increase in ANKTIVA unit sales volume compared to the previous quarter. The positive results were supported by the issuance of a permanent J-code for ANKTIVA and progress in the recombinant BCG Expanded Access Program.
Net product revenue increased by 129% to $16.5 million in Q1 2025 compared to Q4 2024.
ANKTIVA unit sales volume grew by 150% in Q1 2025 over Q4 2024.
Nearly 200 urology practices are registering for ImmunityBio’s recombinant BCG Expanded Access Program.
The company completed a $75 million equity financing in April 2025 to support ongoing operations.
ImmunityBio
ImmunityBio
ImmunityBio Revenue by Segment
Revenue by Segment
Product revenue, net Revenue
CapyFin.comOther revenues Revenue
CapyFin.com Forward Guidance
The company expects continued growth driven by increased ANKTIVA adoption, expanding access through the rBCG EAP, and progress in its pipeline development.
Positive Outlook
- Increased use of ANKTIVA by urologists.
- Addressing the BCG shortage with the launch of the rBCG EAP.
- Opening a new marketplace for therapies through the EAP.
- Progress in developing the pipeline, including a second-line lung cancer study.
- Submission of an EAP protocol for ANKTIVA for the treatment of lymphopenia.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income